A pioneer clinical trial in Spain, in which the Polytechnic University of València, the Institute for Health Research (Incliva) of the Clinical Hospital of Valencia, the Clinic of Barcelona and the upper polytècnica escala of the University of Girona (UDG) participate, will studyThe effectiveness of an artificial pancreas, one of the latest advances of technology applied to health, on 20 patients with type 1 diabetes in treatment with ISCI, ten of each hospital.
As reported by the UPV and the inclusive, the artificial pancreas is a device that is based on a mathematical control algorithm that calculates the "optimal" dose of insulin according to the needs of each patient and at every moment.It is about providing insulin pumps used by patients with type 1 diabetes of an additional system (control algorithm) indicating the amount of insulin "just and necessary for one patient at all times."
The essay is directed at the Valencia clinician by Dr. Javier Ampudia-Blasco, of the Endocrinology Service of the University Clinical Hospital, in collaboration with Paolo Rossetti, of the Fransec de Borja de Gandia Hospital, and researcher of the Incliva.
The essay materializes a research project that dates back to 2004, when researchers from the Institute of Automatic and Industrial Informatics of the UPV-Jorge Bondia-and the Institute of Computer Science and Applications of the University of Girona-Josep VehíFind solutions to avoid "one of the big problems that patients with diabetes still have today, which is to decide the amount of insulin necessary at all times."
Currently, as explained by Jorge Bondia, engineer and co-investigator, "the patient is subjected to intensive insulin therapy, either by multiple daily injections or with continuous infusion by insulin pumps. However, intensive insulin therapy thatIt is very effective, but has as a counterpart the increase in hypoglycemia episodes.
glycemia monitoring
Glycemia monitoring constitutes a "fundamental" element in the treatment and control of diabetic patients.According to Dr. Ampudia-Blasco, "Type 1 diabetes mellitus is a chronic disease that requires the administration of life insulin. Today, in those patients where the administration of multiple insulin injections does not achieve optimal glycemia control, the use of insulin pumps, continuous insulin subcutaneous infusion systems (ISCI), can be an alternative. "
The investigations carried out in recent years have shown that in addition to these ISCI systems, the joint use of an insulin pump and a continuous glucose monitoring system (MCG), "can be useful in selected patients to improve theControl of blood glucose figures. "
However, existing systems so far "do not make decisions automatically, and always require that the patient interprets the glucose figure and decide what to do at all times with respect to the insulin dose to be administered."
The closed handle system or "artificial pancreas" (PA) incorporates an intelligent control algorithm (controller), which interprets the results of the glucose provided by a glucose sensor and decides the amount of insulin to automatically administer, inevery moment.
One of the main problems facing these PA systems is the control of glucose figures after meals and must also decide insulin infusion during the night, where various teams have already demonstrated their effectiveness.The controller interprets the results of theGlucose provided by a glucose sensor and decides, every 15 minutes, the amount of insulin to automatically administered.
The first of the studies took place last week with one of the patients of the Valencia clinician.According to Dr. Juan F. Ascaso, Head of the Endocrinology and Nutrition Service of the Clinic of Valencia, "the artificial pancreas must give autonomy and security to patients, pending to live the disease without obsessions, in addition to avoiding complications derived from glucose declines"
For the general director of Incliva, Rafael Carmena, "This research brings a message of hope to diabetic patients" since the development of artificial pancreatic systems "can contribute to a non -distant future to improve the control of type 1 diabetes,Improve the prognosis and quality of life of patients with this disease. "
Read more: Link
